CFBV

Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

Retrieved on: 
Martedì, Agosto 30, 2022
RNA interference, Liver cancer, CFBV, COVID-19, N-Acetylgalactosamine, HBV, RNA, Securities Exchange Act of 1934, Cirrhosis, Program, Membrane protein, Hepatocyte, Hepatitis B virus, Securities Act of 1933, Arbutus, Patent, Virology, Vaccine, Death, USPTO, Coronavirus, Risk, Hepatitis B, World Health Organization, Antigen, Goal, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, GLOBE, PD, Nasdaq, Immune system, Therapy, NA, Conditional sentence, World, Drug discovery, Annual report, Forward-looking statement, Patient, Pharmaceutical industry

11,427,823, which provides composition of matter patent protection for Arbutus AB-729 RNAi therapeutic product.

Key Points: 
  • 11,427,823, which provides composition of matter patent protection for Arbutus AB-729 RNAi therapeutic product.
  • The patent is expected to provide Arbutus with exclusivity for AB-729 out to at least April 2038.
  • Furthermore, AB-729 has shown achievement of virologic control in five cHBV patients after discontinuing treatment with AB-729 and nucleos(t)ide analog (NA)-therapy.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Agosto 4, 2022
Roivant Sciences, Virology, Journal of Clinical Oncology, Coronavirus, Annual general meeting, COVID-19, Arbutus, VBR, HBsAg, Technology transfer, RNA interference, Degenerative disease, RNA, HBV, ASCO, Patient, Company, ALT, Association, Nasdaq, Safety, Society, American Society of Clinical Oncology, Assembly, Journal, ILC, EASL, Investment, European Association for the Study of the Liver, Antibody, Research, Therapy, Achievement, GLOBE, Severe acute respiratory syndrome coronavirus 2, Â, NA, CFBV, PD-L1, Clinical trial, Vaccine, Pharmaceutical industry, Tutoring, Liver, IND, Vaccitech

WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.

Key Points: 
  • WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.
  • Finally, our financial position is strong with a projected cash runway into the second quarter of 2024.
  • The Company is on-track to report initial data in the second half of 2022.
  • The Company will provide an update with respect to the status and timing of this clinical trial in the second half of 2022.

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

Retrieved on: 
Mercoledì, Luglio 20, 2022
Goal, Patient, Conditional sentence, Death, N-Acetylgalactosamine, Severe acute respiratory syndrome coronavirus 2, CFBV, HBsAg, GLOBE, HBeAg, Forward-looking statement, World, Cornerstone, PD, Cirrhosis, Drug discovery, Hepatitis B virus, Securities Act of 1933, Securities Exchange Act of 1934, Risk, RNA interference, Patent, Immune system, COVID-19, Safety, World Health Organization, NA, Assembly, Virology, Hepatitis B, Clinical trial, Liver cancer, VBR, Coronavirus, Nasdaq, Pharmacokinetics, Therapy, Membrane protein, HBV, Hepatocyte, Annual report, Program, Drug Quality and Security Act, Antigen, RNA, Vaccine, Degenerative disease, Pharmaceutical industry, Arbutus

WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that while its partner, Assembly Biosciences, has decided to discontinue development of its investigational hepatitis B virus core inhibitor candidate vebicorvir (VBR), it plans, in consultation with Assembly Biosciences, to continue dosing patients in the Phase 2a triple combination clinical trial evaluating its proprietary RNAi therapeutic, AB-729, VBR and nucleos(t)ide analogue (NA) therapy for the treatment of patients with chronic HBV infection (cHBV). Preliminary data from the trial are expected in the second half of 2022.

Key Points: 
  • We intend, in collaboration with Assembly, to continue the clinical trial in order to fully and accurately assess the results.
  • The results from this trial coupled with the additional data we anticipate collecting from our capsid inhibitor program will help inform our go-forward combination strategy in the development of cHBV treatments."
  • AB-729 targets hepatocytes using Arbutus novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Retrieved on: 
Mercoledì, Luglio 20, 2022
Virus, CFBV, GLOBE, IFNAR, U.S. Securities and Exchange Commission, Doctor of Philosophy, Arbutus, SEC, Research, C1-inhibitor, Hepatitis B virus, Securities Act of 1933, Workforce, Securities Exchange Act of 1934, Degenerative disease, RNA interference, COVID-19, Safety, AO, HDV, Assembly, Virology, Webcast, CccDNA, Review, VBR, Â, MD, Patient, Pharmacokinetics, SVP, Sumathi Best Television Current Reporting Award, Therapy, Annual report, Program, Maritime Transportation Security Act of 2002, HBV, Pharmaceutical industry, Fine chemical, Vaccine, Management

SOUTH SAN FRANCISCO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that it is discontinuing further development of its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes clinical development of its next-generation core inhibitors, ABI-H3733 (3733) and ABI-4334 (4334), and advances its research pipeline. Assembly Bio will restructure the organization and reduce its workforce to align with these strategic goals.

Key Points: 
  • Assembly Bio will restructure the organization and reduce its workforce to align with these strategic goals.
  • Assembly Biosciences will discontinue clinical development of its first-generation investigational core inhibitor, VBR, based on review of interim on-treatment efficacy from the two ongoing VBR triple combination studies.
  • Luisa Stamm, MD, PhD, the current Assembly Bio chief medical officer, will leave the company at the end of this month.
  • Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
Lunedì, Giugno 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus’ RNAi therapeutic candidate, AB-729, in combination with Vaccitech’s T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NA) therapy for the treatment of patients with virologically-suppressed chronic HBV infection (cHBV).

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

Retrieved on: 
Lunedì, Giugno 6, 2022
ILC, Assembly, EASL, European Association for the Study of the Liver, Securities Exchange Act of 1934, Drug Quality and Security Act, Pharmacokinetics, Annual report, CccDNA, AO, Hepatitis B virus, CFBV, Annual general meeting, Therapy, U.S. Securities and Exchange Commission, GLOBE, Patient, Sumathi Best Television Current Reporting Award, HBV, DNA, COVID-19, SAN, SEC, Securities Act of 1933, MD, Association, Degenerative disease, Safety, Pharmaceutical industry, Liver

The Phase 1b clinical trial is a randomized, multi-center, double-blind and placebo-controlled study that will evaluate the safety, pharmacokinetics and antiviral activity of 3733 in adults with chronic HBV (cHBV) infection.

Key Points: 
  • The Phase 1b clinical trial is a randomized, multi-center, double-blind and placebo-controlled study that will evaluate the safety, pharmacokinetics and antiviral activity of 3733 in adults with chronic HBV (cHBV) infection.
  • The dose-escalation trial will enroll approximately 50 patients with diagnosed cHBV infection who are treatment nave or who are off treatment.
  • Additional information about the Phase 1b clinical trial will be available at www.clinicaltrials.gov .
  • Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 296 million people living with hepatitis B virus (HBV) worldwide.

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
Lunedì, Giugno 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, OXFORD, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 12, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Risk, Disease, Toxicity, HBV, Research, U.S. Securities and Exchange Commission, Nasdaq, News, Patient, Hepatitis, Investment, Antibody, Hand, Therapy, CFBV, Liver, Â, ASGR1, TLR8, Program, Safety, Security (finance), Cancer, Gastrointestinal tract, Vaccine, Gorilla

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Initiated Phase 1-enabling toxicology study for SBT8230 in the first quarter of 2022 and on track to complete Phase 1 regulatory submission in the fourth quarter of 2022.
  • Silverback continues to advance discovery programs, with an update anticipated in the fourth quarter of 2022.
  • For the first quarter ended March 31, 2022, Silverback reported a net loss of $24.6 million, compared to a net loss of $18.9 million for the comparable period in 2021.

Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 5, 2022
COVID-19, Investment, Hepatitis B, Assembly, Nasdaq, Degenerative disease, GLOBE, RNA, CFBV, Company, Research, EASL, HBV, Â, Patient, Coronavirus, Clinical trial, Technology transfer, Virology, RNA interference, Therapy, 2021 Essex County Council election, NA, Severe acute respiratory syndrome coronavirus 2, VBR, Roivant Sciences, Vaccine, Pharmaceutical industry, Cryptocurrency, IND, Vaccitech

WARMINSTER, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its first quarter 2022 financial results and provides pipeline updates.

Key Points: 
  • WARMINSTER, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its first quarter 2022 financial results and provides pipeline updates.
  • Additionally, we have had seven abstracts accepted at the EASL International Liver Congress, which include some of these data.
  • Report data set from the AB-836-001 clinical trial evaluating multiple doses of AB-836 in cHBV patients in the first half of 2022.
  • Advance an oral compound that inhibits the SARS-CoV-2 nsp5 main protease into IND enabling studies in the second half of 2022.

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Marzo 3, 2022
Investment, World, RNA, Assembly, Hepatitis B, COVID-19, Hepatitis, Cornerstone, Partnership, Nasdaq, CccDNA, Patent, CFBV, Method, Therapy, RNA interference, Company, Clinical trial, District, Virology, Severe acute respiratory syndrome coronavirus 2, World Health Organization, HBsAg, Research, Peripheral neuropathy, Douglas v. U.S. District Court ex rel Talk America, MRNA-1273, Degenerative disease, Sale, HBV, VBR, Coronavirus, Immune system, NA, Patient, Hospital, Safety, LNP, Membrane protein, Travel, Arbutus, District court, GLOBE, Vaccine, Pharmaceutical industry, Construction, Geneve 9640, Vaccitech, IND, Roivant Sciences, Tenofovir disoproxil

WARMINSTER,Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.

Key Points: 
  • WARMINSTER,Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its fourth quarter and year end 2021 financial results and provides pipeline updates.
  • 2021 was a transformative year for Arbutus as we greatly expanded our development efforts in Hepatitis B and coronavirus infections, including SARS-CoV-2, said William Collier, Arbutus President and Chief Executive Officer.
  • Arbutus has commenced IND-enabling studies for AB-101 and intends to complete those studies in the second half of 2022.
  • Arbutus, and Genevant, do not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273.